CMO/CDMO Biotechnology Market Size Forecasted to Hit USD 34.1 Billion by 2033 | Persistence Market Research

CMO/CDMO Biotechnology Market

The Contract Manufacturing Organizations (CMO) and Contract Development and Manufacturing Organizations (CDMO) biotechnology market is experiencing significant growth, driven by an increasing demand for biopharmaceuticals, advancements in biologics, and expanding biomanufacturing capabilities. In 2022, the market was valued at approximately USD 10.2 billion, and it is projected to grow at a compound annual growth rate (CAGR) of 11.6% from 2023 to 2033, reaching a valuation of USD 34.1 billion by 2033. This growth reflects the rising demand for high-quality, cost-effective manufacturing services that are critical for the development and production of biologic drugs, biosimilars, and vaccines.

The CMO/CDMO market is a vital part of the biotechnology and pharmaceutical industries, as it supports drug manufacturers by providing specialized services like drug development, manufacturing, and testing. With a market share of 69.2% held by the top five countries, the North American region, particularly the U.S., dominates the global CMO/CDMO biotechnology market. This is primarily due to the high number of mergers and acquisitions among U.S.-based companies, the adoption of innovative manufacturing technologies, and a robust regulatory environment that fosters growth in the pharmaceutical sector. The increasing focus on biologics, gene therapies, and monoclonal antibodies further solidifies the U.S.'s position as a leader in the market.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/32516

Key Highlights from the Report

• The global CMO/CDMO biotechnology market reached a value of USD 10.2 billion in 2022.
• The market is projected to grow at a CAGR of 11.6%, reaching USD 34.1 billion by 2033.
• The stand-alone services segment holds a dominant position in the market.
• The U.S. accounted for 89.4% of the North American market share in 2022.
• South Korea holds the largest share in the East Asian market, with a 70.6% market share in 2022.
• The monoclonal antibodies segment is expected to grow at a CAGR of 13.2% from 2023 to 2033.

Market Segmentation

The CMO/CDMO biotechnology market can be segmented based on service type, product type, expression system, company size, and scale of operations. The stand-alone services segment, which includes services such as bio-manufacturing, analytical testing, and clinical supply, dominated the market in 2022, holding 62.2% of the market share. This is largely due to the increasing need for specialized services from pharmaceutical and biotechnology firms, particularly in cell-line development, which is critical for the production of biologic drugs and biosimilars.

Additionally, the monoclonal antibodies (mAbs) segment is one of the leading product categories in the market, contributing to 41.9% of the total market share in 2022. The segment is expected to grow at a significant rate, driven by the rising success rates in the development and approval of monoclonal antibody therapeutics. The use of mAbs in treating conditions such as cancer, autoimmune diseases, and infectious diseases has substantially increased, leading to a higher demand for manufacturing services from CDMOs.

Regional Insights

North America holds the largest share of the global CMO/CDMO biotechnology market, with the U.S. accounting for 89.4% of the region's market share in 2022. The U.S. market is characterized by a high number of acquisitions and mergers among local companies, which contribute to enhanced service offerings and the growth of single-use bioreactors in the biopharmaceutical sector. This trend is expected to continue as biopharmaceutical companies in the U.S. increasingly adopt more efficient manufacturing processes to meet the rising demand for biologics and vaccines.

In the East Asian market, South Korea stands out as a prominent player, holding a 70.6% market share in 2022. The country's extensive range of developmental services, including cell-line creation, process development, and formulation analysis, positions it as a key player in the global market. The country's strategic investments in advanced biotechnology infrastructure and its role as a manufacturing hub for biopharmaceuticals are expected to fuel its market growth, which is projected to reach a CAGR of 15.2% by 2033.

Market Drivers

Several key factors are driving the growth of the CMO/CDMO biotechnology market. First, the increasing demand for biologics and biosimilars, particularly monoclonal antibodies, is pushing pharmaceutical companies to seek specialized manufacturing services. The success of biologic drugs in treating chronic diseases and cancers, combined with the launch of biosimilars, creates a strong demand for contract manufacturing services to scale production.

Second, the expansion of cell and gene therapy services presents a lucrative growth opportunity for CDMOs. Companies are increasingly investing in the development and scaling of new biologics, leading to a rise in the demand for contract development and manufacturing services. The emergence of novel biologic and biosimilar manufacturing techniques is further propelling the market forward, with technological advancements offering the potential to increase production capacity while lowering costs.

Market Restraints

Despite the market's promising growth, several challenges could potentially hinder its expansion. One significant restraint is the high capital investment required for setting up and maintaining contract manufacturing facilities. Building new biopharmaceutical plants involves considerable financial resources, with costs often ranging from USD 1 billion to USD 2 billion per facility. These high initial costs, coupled with long timelines for construction and certification, can deter smaller companies from entering the market.

Additionally, the shortage of qualified professionals in the biotechnology and pharmaceutical industries is a major concern. As the demand for specialized services continues to rise, the industry faces a talent gap, particularly in emerging markets where expertise in advanced biomanufacturing processes is limited. This shortage of skilled workers could impede the growth of CDMOs and CMOs, especially in regions that require a highly trained workforce to manage complex biotechnological processes.

Market Opportunities

The CMO/CDMO biotechnology market presents numerous opportunities for growth. One of the most notable opportunities lies in the rising adoption of advanced manufacturing technologies, such as single-use bioreactors and automated systems, which offer cost-effective, flexible, and scalable solutions for biopharmaceutical production. These innovations are expected to attract more pharmaceutical companies to outsource their manufacturing needs to CMOs/CDMOs, thus driving the market forward.

Moreover, the increasing demand for personalized medicine and precision therapies opens up new avenues for CDMOs specializing in cell and gene therapy. These therapies require highly specialized manufacturing capabilities, and CDMOs that can offer end-to-end services in gene and cell therapy production are well-positioned to capitalize on this emerging market.

Reasons to Buy the Report

✔ Comprehensive analysis of the market trends, growth drivers, and challenges
✔ Insights into key regions contributing to the market growth
✔ In-depth market segmentation by service type, product type, and expression system
✔ Detailed overview of major companies and recent developments in the industry
✔ Data-driven projections of market size and growth from 2023 to 2033

Company Insights

The key players in the CMO/CDMO biotechnology market include:

• Lonza Group
• Samsung Biologics
• AGC Biologics
• WuXi AppTec
• Catalent, Inc.
• Thermo Fisher Scientific

Recent Developments:

1. In 2020, Lonza introduced its New GSv9TM media and feeds platform, aimed at improving the production of recombinant proteins and enhancing batch-to-batch consistency.

2. Thermo Fisher Scientific expanded its CDMO facility in St. Louis, Missouri, investing USD 50 million to increase single-use capacity in response to growing demand for biologic manufacturing.

By analyzing market trends, opportunities, and challenges, the CMO/CDMO biotechnology market is poised for continued growth, driven by innovations in biologic and biosimilar manufacturing and the increasing need for specialized services from pharmaceutical and biotechnology companies worldwide.

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.